# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Dwight D. Eisenhower (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET015-SYN
- Date: 2026-01-12
- Fictional facility: St. Posthumous Health Center
- Fictional author: Russell Okonkwo, MD
- Calendar frame: modern shifted

## Subjective

The patient participates in this fictional visit for primary care visit to establish care after myocardial infarction and plan a return to full-time work. **S**

## Objective

Total cholesterol: 150 mg/dL; HDL cholesterol: 42 mg/dL; Triglycerides: 150 mg/dL (high); LDL cholesterol: 78 mg/dL; Lipoprotein(a): 22 mg/dL; Sodium: 140 mmol/L; Potassium: 4.4 mmol/L; Creatinine: 1 mg/dL; eGFR: 84 mL/min/1.73 m²; Glucose: 96 mg/dL; Hemoglobin: 14.6 g/dL; Platelets: 228 10*3/uL; HbA1c: 5.6%; ALT: 24 U/L; PHQ-2: 1; AUDIT-C: 1. All results are synthetic.

BP 136/82 mmHg; pulse 62 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 79 kg; BMI 24.9 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Anterior ST-elevation myocardial infarction about four months before intake, treated with a drug-eluting stent to the left anterior descending artery; synthetic modern episode linked to the documented 1955 anterolateral infarction; Coronary artery disease, single-vessel, after stenting; no angina; Hyperlipidemia, on high-intensity statin; Essential hypertension; Former heavy cigarette smoker, quit about seven years before intake. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Continued without change: Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily **S**
- Continued without change: Ticagrelor 90 mg oral tablet, one tablet by mouth twice daily **S**
- Continued without change: Atorvastatin 80 mg oral tablet, one tablet by mouth daily **S**
- Continued without change: Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily **S**
- Stopped: Lisinopril 5 mg oral tablet, one tablet by mouth daily **S**
- Started: Lisinopril 10 mg oral tablet, one tablet by mouth daily **S**
- Started: Ezetimibe 10 mg oral tablet, one tablet by mouth daily **S**
- Continued without change: Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if pain is not better 5 minutes after the first tablet **S**

## Plan

- Dual antiplatelet therapy with aspirin 81 mg and ticagrelor 90 mg twice daily for twelve months after the infarction, then aspirin alone. Guideline: 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes (2025); CMID: Clinical Monitoring Intelligence Database, acute myocardial infarction, ischemic heart disease, hyperlipidemia, and hypertension monographs (2026) **S**
- High-intensity atorvastatin with ezetimibe added for LDL cholesterol above 55 mg/dL; recheck lipids 4 to 12 weeks after the change, then every 3 to 12 months. Guideline: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, acute myocardial infarction, ischemic heart disease, hyperlipidemia, and hypertension monographs (2026) **S**
- Metoprolol succinate and lisinopril for blood pressure below 130/80; basic metabolic panel 1 to 2 weeks after an ACE inhibitor change, then every 6 months; reassess the beta-blocker at one year. Guideline: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, acute myocardial infarction, ischemic heart disease, hyperlipidemia, and hypertension monographs (2026) **S**
- Cardiology consultation to establish local cardiology care, reassess left ventricular function, and advise on return to full-time work and on the duration of antiplatelet and beta-blocker therapy. Guideline: 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes (2025); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023) **S**
- After cardiac rehabilitation, a home maintenance program of brisk walking and golf, a Mediterranean-style diet, staying tobacco free, PHQ-2 depression screening at visits, and a written chest-pain plan with sublingual nitroglycerin. Guideline: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, acute myocardial infarction, ischemic heart disease, hyperlipidemia, and hypertension monographs (2026) **S**
- Yearly influenza vaccine, pneumococcal vaccine, RSV vaccine, and current COVID-19 vaccine. Guideline: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, acute myocardial infarction, ischemic heart disease, hyperlipidemia, and hypertension monographs (2026) **S**
